Radioligand therapy 177Lu-PSMA-617 receives breakthrough designation from the FDA based on better overall survival outcomes in patients with metastatic castration-resistant prostate cancer.
Ariana Pelosci
Advertisement
Ariana Pelosci, assistant managing editor for CancerNetwork® and the journal ONCOLOGY®, has been with the team since June 2021. She specializes in both web and print, and runs the social media accounts for CancerNetwork®.
She graduated from the University of Delaware, where she studied Media Communications and minored in journalism and marketing. At heart, she is a Jersey girl, and you can always find her down the shore during her free time.
Ariana loves to read, specifically historical or contemporary fiction. Follow Ariana on Twitter @APelosci or email her at apelosci@mjhlifesciences.com.
Articles by Ariana Pelosci
Patients who had resection within 12 weeks of diagnosis of stage I NSCLC were found to have lower rates of recurrence.
Bemcentinib plus PD-1/L1 inhibition moves forward as therapy for patients with AXL-expressing non–small cell lung cancer.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Clears Phase 3 Lacutamab Protocol in Cutaneous T-Cell Lymphomas
2
Finding a “Sweet Spot” for Smoldering Multiple Myeloma Management
3
Identifying and Pursuing Optimization of ADC Treatment in Cancer
4
The Show and After Show: What's Happening at the 43rd Annual Chemotherapy Foundation Symposium?
5
